Cargando…
Clinical utility of varenicline for smokers with medical and psychiatric comorbidity
Chronic obstructive pulmonary disease (COPD) is a costly and deadly disease afflicting an estimated 210 million people and accounting for 5% of all global deaths. Exposure to cigarette smoke is the greatest risk factor for COPD in the developed world. Smoking cessation improves respiratory symptoms...
Autores principales: | Ebbert, Jon O, Wyatt, Kirk D, Zirakzadeh, Ali, Burke, Michael V, Hays, JT |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793070/ https://www.ncbi.nlm.nih.gov/pubmed/20037681 |
Ejemplares similares
-
Varenicline for smoking cessation: efficacy, safety, and treatment recommendations
por: Ebbert, Jon O, et al.
Publicado: (2010) -
Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence
por: Burke, Michael V, et al.
Publicado: (2016) -
Varenicline in smokers with diabetes: A pooled analysis of 15 randomized, placebo‐controlled studies of varenicline
por: Tonstad, Serena, et al.
Publicado: (2016) -
Varenicline decreases alcohol consumption in heavy-drinking smokers
por: Mitchell, Jennifer M., et al.
Publicado: (2012) -
The psychiatric effects of varenicline on patients with depression
por: Yeung, EYH, et al.
Publicado: (2015)